Third Age Health Services (TAH)•HY23•Released 28 November 2022Acquisitions lifted revenue 61% but halved NPAT as integration costs bitOrganic growth was only 16.7% and the $0.02449 interim dividend consumes 75% of a weaker profit base, tightening the capital-return cushion.Published 21 April 2026Read briefing→
Green Cross Health (GXH)•HY23•Released 25 November 2022HY23 PBT up 20% and operating cash up 63%, but pharmacy margin slippedCommunity Health and Medical drove the earnings step-up while a higher effective tax rate trimmed NPAT growth below PBT growth.Published 21 April 2026Read briefing→
Blis Technologies (BLT)•HY23•Released 10 November 2022Revenue up 10.2% but losses barely narrow and annualised run-rate trails FY22Operating cash turned positive, but the swing was driven by a sharp working-capital release rather than earnings improvement.Published 21 April 2026Read briefing→
Oceania Healthcare (OCA)•HY23•Released 7 November 2022OCA swings to $32.5m pre-tax loss as net debt jumps to $548mRevenue grew 52% but earnings flipped into loss, operating cash halved, and capex-driven borrowing lifted leverage sharply.Published 22 April 2026Read briefing→
Rua Bioscience (RUA)•FY22•Released 29 August 2022Revenue collapsed 94.6% and NPAT loss widened to $8.6m on tax reversalOperating cash burn accelerated to $6.8m while cash reserves fell to $1.9m, shortening the runway despite borrowings being cleared.Published 22 April 2026Read briefing→
TruScreen Group (TRU)•FY22•Released 30 May 2022Truscreen loss widens 126% to NZ$7.9m as gross margin halves and H2...Revenue grew 48% to NZ$1.7m but cash fell to NZ$2.8m and equity collapsed 70%, raising a funding question the release does not address.Published 23 April 2026Read briefing→
Third Age Health Services (TAH)•FY22•Released 30 May 2022NPAT up 12.6% but PBT essentially flat as lower tax rate did the workRevenue and gross margin expanded on GP acquisitions, but operating cash flow fell 31% and the headline earnings growth is largely a tax-rate effect.Published 21 April 2026Read briefing→
Rua Bioscience (RUA)•HY22•Released 25 February 2022Cash dropped to NZ$2.3m as operating burn nearly doubled to NZ$3.7mRevenue grew 34% off a trivial base while the cash position fell 88% year on year, leaving runway as the central question heading into...Published 22 April 2026Read briefing→
Truscreen Group (TRU)•HY22•Released 29 November 2021Revenue up 25% but operating cash burn widened to NZ$1.7mTopline growth and a debt-free balance sheet sit against a wider cash outflow and a NZ$3.7m cash pile that is now the binding constraint.Published 23 April 2026Read briefing→